Cancer HorizonsAll NewsBlogsCaregivingDiet and ExerciseFinancialPsychosocialRecipesSexual HealthSide EffectSponsoredSurvivorship
All VideosCURE ConnectionsCURE Expert Connections®CURE Speaking OutCURE TVEducated Patient Sound BitesOn Demand: Webinars
Conference Coverage Conference Listing
CURE AdventuresCURE AwardsEducated Patient In Person EducationEducated Patient Virtual Education
Advocacy GroupsArt GalleryClinical Trial CornerHeal®PartnersPodcastsPublicationsShare Your Story
Subscribe
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
Spotlight -
  • Blogs
  • Breast Cancer Webinar Series
  • Cancer Horizons
  • Clinical Trial Corner
  • Heal®
  • Publications
  • Videos
Blood CancersBlood CancersBlood CancersBlood Cancers
Brain Cancer
Breast CancerBreast Cancer
Childhood Cancers
Gastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal CancersGastrointestinal Cancers
Genitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary CancersGenitourinary Cancers
Gynecologic CancerGynecologic CancerGynecologic CancerGynecologic CancerGynecologic Cancer
Head & Neck Cancer
Immunotherapy
LeukemiaLeukemiaLeukemia
Lung CancerLung Cancer
LymphomaLymphomaLymphomaLymphomaLymphoma
Myeloma
Rare CancersRare CancersRare CancersRare Cancers
Sarcoma
Skin CancerSkin Cancer
Thyroid Cancer
    • Subscribe
Advertisement

Article

January 11, 2016

Survivors of Young-Adult Hodgkin Lymphoma Not Getting All Recommended Checkups

Author(s):

Kelly Johnson

Only 30 percent of survivors at high risk for cardiac damage adhered to long-term recommendations including an echocardiogram, electrocardiogram or multigated acquisition (MUGA) scan.

Despite national evidence- and consensus-based guidelines on post-treatment care, less than half of adolescents and young adults (AYAs) who have survived Hodgkin lymphoma receive all of the recommended services within the first year after treatment, according to results of a pilot study to be presented at the 2016 Cancer Survivorship Symposium.

In addition, only 30 percent of survivors at high risk for cardiac damage adhered to long-term recommendations including an echocardiogram, electrocardiogram or multigated acquisition (MUGA) scan.

“When we examine adherence to guidelines like these, it’s actually an important part of high-quality care to see if we can identify gaps and hopefully close them,” lead author, Erin E. Hahn, research scientist, Kaiser Permanente Southern California, Department of Research and Evaluation, said during a press cast held in advance of the symposium.

Hodgkin lymphoma accounts for 12 percent of all new cancer diagnoses among AYAs, and while the overall survival rate is very high, those in this population remain at high risk for short- and long-term effects related to their treatment throughout survivorship.

The study evaluated electronic medical records of 354 AYA patients ages 15 to 39 who were diagnosed with Hodgkin lymphoma between 2000 and 2010. The patients were diagnosed, treated and followed for at least two years at the Kaiser Permanente Southern California integrated health care system.

Using National Comprehensive Cancer Network (NCCN) guidelines, the investigators measured adherence to short-term recommendations, including oncology visits, labs, imaging and the flu vaccine, which was categorized as preventive care.

Nearly all of the patients had annual visits with their oncologists within the first five years after treatment (96 percent), and 70 percent received the recommended labs. Two-thirds received a recommended CT scan within the first year after treatment.

However, only 20 percent of patients received the recommended flu vaccine, bringing overall adherence to 48 percent within the first 12 months.

“I was happy to see that most patients were seeing their oncologists and having some appropriate testing in the first five years after treatment,” Hahn said in a statement. “I think there is work to be done to increase awareness of other guideline recommendations, and potentially access to services.” The study also examined a subgroup of patients who were at least 10 years out of treatment and had received high-dose anthracycline-based chemotherapy plus radiation. NCCN guidelines recommend that this population of high-risk patients receive cardiac screening.

The majority of AYA patients in this population received annual blood pressure testing, but less than half received one of the other recommended modalities — an echocardiogram, electrocardiogram or MUGA scan.

Researchers noted that AYA patients who were diagnosed with Hodgkin lymphoma between 2006 and 2010 were more likely to adhere to post-treatment recommendations than those diagnosed between 2000 and 2005.

“One of our hypotheses was that, as these guidelines became more familiar to clinicians and hopefully also to our patients, it might actually change the patterns of care that we see,” Hahn said, “and that did turn out to be true.”

The study authors plan to expand their research to include a larger cohort of patients and investigate long-term recommended services. Hahn noted that next steps involve designing and implementing systematic programs to address gaps in recommended care for the AYA patient population.

Presscast moderator and ASCO expert Merry-Jennifer Markham added that Hahn’s study highlights a need for further interventions.

“The survivorship care is really crucial in the adolescent and young adult population of Hodgkin lymphoma survivors because many of them — most of them, in fact — have long lives ahead of them,” she said.

“Clearly, we have some opportunities ahead of us to improve adherence to post-treatment guidelines and hopefully, as a result, survivorship outcomes for all.”

Newsletter

Stay up to date on cancer updates, research and education

Subscribe Now!
Related Videos
Image of carly.
Facing Cancer as an AYA and Navigating Fertility Preservation Choices
Image of kelly.
Preparing For Survivorship After Lymphoma Treatment in AYA PatientsPreparing For Survivorship After Lymphoma Treatment in AYA Patients
Image of doctor.
Understanding AYA Lymphoma Care and Why Treatment May Differ by Age
Image of Dr. Kelly
Breaking Down Barriers to Diagnosis in AYA Patients With Lymphoma
image of doctor D'Sa
Mitigating Peripheral Neuropathy During Cancer Treatment
Some patients with relapsed/refractory diffuse large B-cell lymphoma whose disease progressed after CAR-T cell therapy, responded to odronextamab.
Odronextamab Elicits Responses in Some With Lymphoma Following CAR-T
Image of woman with brown hair.
Raising Awareness for Adolescents and Young Adults with Cancer
Dr. Frederick L. Locke sat down with CURE® to discuss treatment with cema-cel in the ALPHA/ALPHA2 studies for relapsed/refractory large B-cell lymphoma.
Breaking Down The Results of The ALPHA/ALPHA2 Study in Large B-Cell Lymphoma
Treatment with cemacabtagene ansegedleucel demonstrated responses in patients with relapsed or treatment-resistant large B-cell lymphoma.
Off-The-Shelf CAR T Therapy Elicits Responses in Large B-Cell Lymphoma
Dr. Sattva S. Neelapu is a professor and deputy department chair in the Department of Lymphoma/Myeloma, Division of Cancer Medicine, at The University of Texas MD Anderson Cancer Center, in Houston, as well as a member of Graduate Faculty, Immunology Program, Graduate School of Biomedical Sciences, at The University of Texas Health Science Center, also located in Houston.
Understanding the Challenges of CAR T-Cell Therapy Treatment in R/R NHL
Related Content
Advertisement
A patient with relapsed follicular lymphoma achieved complete remission one month after PMB-CT01 treatment: © stock.adobe.com.
May 22nd 2025

PMB-CT01 Therapy Induces Complete Remission in Follicular Lymphoma

Spencer Feldman
A patient with relapsed follicular lymphoma achieved complete remission one month after PMB-CT01 treatment in the phase 1 PMB-102 trial.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
Image of blood cell.
May 12th 2025

Understanding the Evolving Strategies in WM Care and Management

Ryan Scott
An expert reflects on the treatment landscape of Waldenström macroglobulinemia, emphasizing diagnostics, collaboration and managing neuropathy effectively.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
Blood cell.
May 8th 2025

Navigating Lymphoma and Survivorship in Adolescents and Young Adults

Ryan Scott
Dr. Kara Kelly discusses the unique challenges that adolescent and young adult patients with cancer face following their diagnosis.
Kim Johnson was a caregiver for her sister while she battled stage 4 Hodgkin Lymphoma for nearly five years, from diagnosis through an autologous transplant. Catch up on all of Kim's blogs here!
May 7th 2025

A Nurse Who Became Family After a Cancer Diagnosis

Kim Johnson
Eric Z. cared for my sister and mentored me with compassion, wisdom and unwavering presence — shaping my path in nursing and life.
Related Content
Lymphoma
Lymphoma
Advertisement
A patient with relapsed follicular lymphoma achieved complete remission one month after PMB-CT01 treatment: © stock.adobe.com.
May 22nd 2025

PMB-CT01 Therapy Induces Complete Remission in Follicular Lymphoma

Spencer Feldman
A patient with relapsed follicular lymphoma achieved complete remission one month after PMB-CT01 treatment in the phase 1 PMB-102 trial.
CURE Cancer Horizons podcast logo
January 29th 2024

Prostate Cancer Headlines, CAR-T Warnings and Laughter Therapy

Alex Biese Brielle Benyon
CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.
Image of blood cell.
May 12th 2025

Understanding the Evolving Strategies in WM Care and Management

Ryan Scott
An expert reflects on the treatment landscape of Waldenström macroglobulinemia, emphasizing diagnostics, collaboration and managing neuropathy effectively.
Top Headlines on CAR-T Cell Therapy
December 4th 2023

Top Headlines on CAR-T Cell Therapy

Alex Biese Brielle Benyon
From FDA concerns to a potential new drug, CAR-T cell therapies were dominating oncology headlines last week.
Blood cell.
May 8th 2025

Navigating Lymphoma and Survivorship in Adolescents and Young Adults

Ryan Scott
Dr. Kara Kelly discusses the unique challenges that adolescent and young adult patients with cancer face following their diagnosis.
Kim Johnson was a caregiver for her sister while she battled stage 4 Hodgkin Lymphoma for nearly five years, from diagnosis through an autologous transplant. Catch up on all of Kim's blogs here!
May 7th 2025

A Nurse Who Became Family After a Cancer Diagnosis

Kim Johnson
Eric Z. cared for my sister and mentored me with compassion, wisdom and unwavering presence — shaping my path in nursing and life.
Advertisement
Advertisement
Advertisement
x
About Us
Advertise / Support
Editorial Board
Contact Us
CancerNetwork.com
TargetedOnc.com
OncLive.com
OncNursingNews.com
Terms & Conditions
Privacy
Do Not Sell My Information
Contact Info

2 Commerce Drive
Cranbury, NJ 08512

609-716-7777

© 2025 MJH Life Sciences

All rights reserved.